Source:http://linkedlifedata.com/resource/pubmed/id/11535875
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2001-9-5
|
| pubmed:abstractText |
Colorectal cancer is the second most frequent cause of death from cancer in western countries. Many lines of evidence suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may offer chemoprevention against colorectal cancer. A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence. We now report the baseline characteristics of subjects enrolled into the trial. Results: A total of 618 polyps were excised from 274 patients at the baseline colonoscopy. Men had on average (+/-SD) 2.5 +/- 1.8 polyps per subject and women had 1.7 +/- 1.2. Ninety-one (33.7%) had three or more adenomas and 183 (67.8%) had more than one adenoma measuring 10 mm or more in diameter. The mean (+/-SD) age of the subjects was 57.7 (+/- 9.4) years. Sixty-seven (24.9%) reported that they had previously had adenoma(s), 95 (35.2%) reported a family history of colorectal cancer and 41 (15.2%) a family history of colorectal adenomas. Perspective: All subjects will undergo a one-year clearance colonoscopy by February 2001. Clinical, molecular biological and dietary data will enable us to investigate other factors influencing the recurrence of adenomas in this group of high-risk subjects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0959-8278
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
327-35
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11535875-Adenoma,
pubmed-meshheading:11535875-Administration, Oral,
pubmed-meshheading:11535875-Adult,
pubmed-meshheading:11535875-Aged,
pubmed-meshheading:11535875-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:11535875-Aspirin,
pubmed-meshheading:11535875-Colonoscopy,
pubmed-meshheading:11535875-Colorectal Neoplasms,
pubmed-meshheading:11535875-Dose-Response Relationship, Drug,
pubmed-meshheading:11535875-Double-Blind Method,
pubmed-meshheading:11535875-Female,
pubmed-meshheading:11535875-Humans,
pubmed-meshheading:11535875-Male,
pubmed-meshheading:11535875-Middle Aged,
pubmed-meshheading:11535875-Neoplasm Recurrence, Local,
pubmed-meshheading:11535875-Prospective Studies,
pubmed-meshheading:11535875-Research Design,
pubmed-meshheading:11535875-Risk Factors
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings.
|
| pubmed:affiliation |
Service de gastro-enterologie, Hôpital Avicenne, 125 rue de Stalingrad, 93009 Bobigny Cedex, France. robert.benamouzig@avc.ap-hop-paris.fr
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|